POMDOCTOR Ltd

POMDOCTOR LIMITED announced it received two letters from Nasdaq indicating deficiencies in continued listing requirements. The company no longer meets the minimum market value of listed securities (MVLS) of $50 million and the minimum market value of publicly held shares (MVPHS) of $15 million. POMDOCTOR has 180 days, until April 26, 2027, to regain compliance for both requirements. Failure to do so could lead to delisting, though the company may appeal the decision. The company is evaluating options to meet these requirements.

POMDOCTOR LIMITED announced its differentiated 'hardware + AI + payment' healthcare infrastructure model. The company aims to evolve into a comprehensive digital healthcare technology infrastructure provider by integrating continuous health monitoring, AI-powered analysis, physician intervention, and healthcare payment within a unified ecosystem. This approach is designed to offer advantages in healthcare compliance, data collection via proprietary wearables, and seamless integration with payment networks, differentiating it from traditional internet healthcare platforms.

POMDOCTOR LIMITED highlighted its healthcare intelligence flywheel, a closed-loop growth model that integrates AI, wearable devices, healthcare data, professional medical services, and insurance payment networks. The company believes this model enables each healthcare service cycle to generate incremental data, continuously strengthen AI analytics, enhance service personalization, and boost user engagement. This iterative process is designed to create a self-sustaining growth cycle and a system-level competitive barrier in predictive healthcare. CEO Zhenyang Shi emphasized the model's ability to deliver more personalized, higher-quality services and build a smarter, more scalable infrastructure.

POMDOCTOR Limited detailed its four-tier diversified revenue structure, aiming to leverage established B2C healthcare operations with new technology-enabled services. The company reported net revenues of RMB399.9 million (US$59.04 million) in fiscal year 2025 from its B2C segment. The strategy includes AI-enabled chronic disease membership subscriptions, B2B enterprise and hospital services, and pharmaceutical RWS/RWD services to drive recurring revenue and long-term value.

POMDOCTOR Limited announced its ongoing efforts to strengthen its healthcare data ecosystem to enhance AI-powered chronic disease management. The company is leveraging real-world data (RWD), artificial intelligence (AI), wearable technologies, and remote patient monitoring (RPM) to enable personalized and predictive healthcare. Market projections indicate significant growth for the global RWD market, with estimates ranging from $2.15 billion in 2026 to $7.11 billion by 2035, driven by increased adoption in clinical research and personalized healthcare solutions.

POMDOCTOR Ltd announced it has regained compliance with Nasdaq's minimum bid price requirement. The company received a letter from Nasdaq on July 10, 2026, confirming that its American Depositary Shares (ADS) maintained a closing bid price of $1.00 or greater for 10 consecutive business days, from June 25 to July 9, 2026. This resolves the previous non-compliance notification received on January 29, 2026, ensuring the continued listing of Pomdoctor's ADS on Nasdaq.

POMDOCTOR Limited highlighted its ongoing efforts to build an AI-powered chronic disease management ecosystem. The company is integrating artificial intelligence, remote patient monitoring, wearable technologies, and real-world healthcare data to evolve into a predictive, continuous, and personalized healthcare service provider. This strategy aligns with market trends, as the global AI chronic disease prevention market is projected to grow significantly from $30.2 billion in 2026 to $488.4 billion by 2035.

POMDOCTOR Limited announced a strategic upgrade, officially positioning itself as a foundational infrastructure provider for predictive healthcare data and services. The company is evolving from a traditional online healthcare platform to an AI-enabled healthcare infrastructure provider, integrating wearable technologies, AI, physician services, real-world healthcare data, and healthcare payment networks. This shift aims to create an intelligent healthcare ecosystem that enables predictive, continuous, and personalized healthcare, moving from reactive treatment to proactive health management. The company also plans to develop a diversified revenue model beyond pharmaceutical sales and pursue international growth, starting with the United States.

POMDOCTOR Limited announced that its previously disclosed ADS ratio change will become effective on June 22, 2026. The ratio will change from one ADS representing one-sixth Class A ordinary share to one ADS representing three Class A ordinary shares, which is equivalent to a one-for-eighteen reverse ADS split. Existing ADS holders will have their shares automatically exchanged, and the ADSs will begin trading on a post-split basis under the same ticker "POM" on the effective date. Fractional entitlements will be sold for cash.

POMDOCTOR LIMITED announced a plan to change the ratio of its American Depositary Shares (ADSs) to its Class A ordinary shares. The current ratio of one ADS representing one-sixth Class A ordinary share will change to one ADS representing three Class A ordinary shares. This adjustment will have the same effect as a one-for-eighteen reverse ADS split for existing ADS holders, with an anticipated effective date around June 22, 2026. The company expects the trading price of its ADSs to increase proportionately.